The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bridged Bicyclo Compounds, Heterocyclic
/ pharmacology
Humans
Leukemia, Myeloid, Acute
/ metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Proto-Oncogene Proteins c-bcl-2
/ metabolism
Quality of Life
Sulfonamides
BCL-2
acute lymphocytic leukemia
venetoclax
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Sep 2022
19 Sep 2022
Historique:
received:
30
08
2022
revised:
14
09
2022
accepted:
16
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Venetoclax, a B-cell lymphoma (BCL-2) inhibitor, in combination with hypomethylating agents has become the new standard of care in elderly and unfit patients with acute myeloid leukemia, with significantly improved overall survival and quality of life. Studies of venetoclax combined with high-dose chemotherapy are emerging with evidence of higher rates of molecular remission. Recently, a growing number of publications bring forth the use of venetoclax in patients with acute lymphoblastic leukemia (ALL). In the current review, we present the biological rationale of BCL-2 inhibition in ALL, how the interplay of BH3 proteins modulate the response and the current clinical experience with various combinations.
Identifiants
pubmed: 36142863
pii: ijms231810957
doi: 10.3390/ijms231810957
pmc: PMC9504828
pii:
doi:
Substances chimiques
Bridged Bicyclo Compounds, Heterocyclic
0
Proto-Oncogene Proteins c-bcl-2
0
Sulfonamides
0
venetoclax
N54AIC43PW
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Blood Adv. 2020 Jun 23;4(12):2762-2767
pubmed: 32569380
Leuk Lymphoma. 2021 Dec;62(13):3300-3303
pubmed: 34323656
Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
pubmed: 18097445
Nat Genet. 2015 Sep;47(9):1020-1029
pubmed: 26214592
Blood. 2014 Dec 11;124(25):3738-47
pubmed: 25301704
Hemasphere. 2022 Feb 24;6(3):e701
pubmed: 35233509
In Vivo. 2020 Mar-Apr;34(2):511-516
pubmed: 32111748
Cancer Discov. 2019 Jul;9(7):910-925
pubmed: 31048320
J Clin Oncol. 2021 Sep 1;39(25):2768-2778
pubmed: 34043428
Blood. 2013 Aug 29;122(9):1587-98
pubmed: 23881917
Leuk Lymphoma. 2021 Sep;62(9):2292-2294
pubmed: 33691573
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Cell Rep. 2015 Dec 29;13(12):2715-27
pubmed: 26711339
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):212-218
pubmed: 32035785
Sci Transl Med. 2016 Aug 31;8(354):354ra114
pubmed: 27582059
Ann Hematol. 2020 Feb;99(2):395-397
pubmed: 31879788
N Engl J Med. 2020 Oct 22;383(17):1613-1623
pubmed: 33085860
Blood. 2021 Sep 30;138(13):1120-1136
pubmed: 34320168
Cancer Discov. 2021 Jun;11(6):1440-1453
pubmed: 33593877
Nature. 2011 Oct 02;478(7370):529-33
pubmed: 21964340
Leukemia. 2019 Jan;33(1):262-266
pubmed: 30008477
Ann Hematol. 2022 Mar;101(3):697-699
pubmed: 33954816
Blood. 2007 Sep 15;110(6):2057-66
pubmed: 17536015
Signal Transduct Target Ther. 2022 Feb 21;7(1):51
pubmed: 35185150
Blood. 2008 Feb 15;111(4):2300-9
pubmed: 18056841
Blood. 2014 Jun 12;123(24):3739-49
pubmed: 24740809
Blood Cancer J. 2022 Jan 28;12(1):20
pubmed: 35091541
Blood. 2016 Sep 8;128(10):1382-95
pubmed: 27343252
Cell Death Dis. 2015 Jan 15;6:e1593
pubmed: 25590803
Cell Stem Cell. 2013 Mar 7;12(3):316-28
pubmed: 23333150
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):246-251
pubmed: 32199933
Am J Hematol. 2021 Jul 1;96(7):E229-E232
pubmed: 33780038
Cancers (Basel). 2021 Dec 29;14(1):
pubmed: 35008312
Blood. 2012 Jun 14;119(24):5807-16
pubmed: 22538851
Cell Death Dis. 2019 Jul 29;10(8):571
pubmed: 31358732
Br J Haematol. 2008 Jun;141(6):827-39
pubmed: 18422996
Mol Pharmacol. 2010 Mar;77(3):483-94
pubmed: 20038611
Nat Cancer. 2020 Dec;1(12):1176-1187
pubmed: 33884374
Leukemia. 2011 Feb;25(2):321-30
pubmed: 21072044
JCO Precis Oncol. 2018;2:
pubmed: 31080940
Expert Rev Hematol. 2018 May;11(5):391-402
pubmed: 29561706
Biomark Res. 2021 Dec 20;9(1):92
pubmed: 34930453
Clin Case Rep. 2020 Jul 07;8(10):2000-2002
pubmed: 33088538
Case Rep Hematol. 2018 Aug 26;2018:6092646
pubmed: 30225152
Cancer Res. 2015 Apr 1;75(7):1366-75
pubmed: 25649768
Leukemia. 2017 Oct;31(10):2037-2047
pubmed: 28074072
Blood. 2017 Mar 16;129(11):e26-e37
pubmed: 28122742
Cancer Discov. 2014 Sep;4(9):1074-87
pubmed: 24994123
Clin Cancer Res. 2014 Sep 1;20(17):4520-31
pubmed: 25013123
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Ann Hematol. 2022 May;101(5):1141-1144
pubmed: 34661714
Blood Adv. 2021 Dec 28;5(24):5501-5506
pubmed: 34610112
Cancer Res. 2019 May 1;79(9):2339-2351
pubmed: 30862722